measles, mumps, and rubella vaccine (MMR)
GPTKB entity
Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
injection
|
| gptkbp:approves |
gptkb:1971
|
| gptkbp:associated_with |
vaccine-preventable diseases
Herd immunity community immunity reduction in hospitalizations reduction in mortality rates |
| gptkbp:available_in |
most countries
|
| gptkbp:combination_vaccine |
yes
|
| gptkbp:community_health |
reduced incidence of diseases
|
| gptkbp:contains |
live attenuated viruses
|
| gptkbp:contraindication |
immunocompromised individuals
severe allergic reaction |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
measles, mumps, and rubella vaccine (MMR)
|
| gptkbp:influenced_by |
gptkb:media_coverage
healthcare policies public perception scientific studies |
| gptkbp:informed_consent_required |
yes
|
| gptkbp:introduced_in |
gptkb:United_States
|
| gptkbp:is_effective_against |
over 80% for mumps
over 90% for measles over 90% for rubella |
| gptkbp:is_informed_by |
gptkb:guidelines
|
| gptkbp:is_linked_to |
autism controversy
outbreaks when coverage is low |
| gptkbp:is_monitored_by |
adverse reactions
|
| gptkbp:is_protected_by |
gptkb:rubella
gptkb:measles mumps |
| gptkbp:is_recommended_by |
gptkb:CDC
gptkb:WHO |
| gptkbp:is_recommended_for |
gptkb:children
|
| gptkbp:is_vulnerable_to |
live attenuated vaccine
exists in some populations high in developed countries low in some developing countries |
| gptkbp:part_of |
immunization programs
childhood vaccination schedule MMR vaccination campaign |
| gptkbp:performance |
second dose at 4-6 years
first dose at 12-15 months |
| gptkbp:requires |
healthcare provider administration
|
| gptkbp:requires_storage_at |
refrigerated temperatures
|
| gptkbp:side_effect |
fever
rash thrombocytopenia swelling of glands febrile seizures |
| gptkbp:bfsParent |
gptkb:Measles
|
| gptkbp:bfsLayer |
5
|